Lauren's practice focuses on advising clients through complex health care transactions and regulatory matters. She has served as health care counsel on numerous private equity and strategic transactions, including mergers and acquisitions, joint ventures, affiliations, and investments involving pharmacies, PBMs, physician practices, long-term care facilities, third party payors, value-based contracting entities, nurse staffing companies, and health care technology firms.
Lauren’s deal work is complimented by her regulatory practice, which primarily focuses on advising pharmacies, PBMs, managed care organizations and other clients in the payor space. Drawing from her experience working for the Federal Coordinated Health Care Office (the “Duals Office”) within the Centers for Medicare & Medicaid Services (“CMS”), she is able to provide practical advice to clients on regulatory and compliance issues relating to Medicare Advantage, Medicare Part D and Medicaid. She has advised clients on Medicare Advantage and Medicare Part D applications, audit appeals, contract negotiations, Medicaid managed care RFPs, and payment issues.
Lauren’s regulatory practice also focuses on compliance with the anti-kickback statute, corporate practice of medicine and fee-splitting prohibitions, telemedicine, and prescribing and licensing requirements (including change of ownership requirements).
Prior to her tenure with CMS, she was a research consultant with a health care consulting company in the DC area, working primarily with state Medicaid agencies and Medicaid managed care plans.
Experience
viewpoints
News & Press
podcasts
Events & Speaking
Recognition & Awards
Recent Insights
Member Lauren Moldawer was quoted by Healthcare Brew on how pharmacy benefit managers (PBMs) are reacting to a proposed change to the Medicare Part D Program. This change would allow pharmacies to terminate contracts without cause and without permission from the PBM, which Lauren said could create uncertainty for PBMs.
Member Lauren Moldawer spoke with Endpoints News about how the Trump administration might approach Medicare drug price negotiations under the Inflation Reduction Act (IRA) going forward.
